This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Vitamin D Dose Finding Study

This study has been completed.
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:
NCT01092338
First received: March 23, 2010
Last updated: August 1, 2013
Last verified: August 2013
History of Changes
Results First Received: January 7, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: HIV Infections
AIDS
Intervention: Drug: Cholecalciferol (Vit D3)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The Study started enrollment in 01/2010 and completed in 01/2011. A total of 44 subjects were enrolled including 19 with perinatally-acquired HIV/AIDS (PA) and 25 with behaviorally-acquired HIV/AIDS (BA).

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects taking a vitamin D supplement or multi-vitamin were eligible if they were willing to discontinue supplementation after a minimum of a 2 month washout period.

Reporting Groups
  Description
4000IU/d of Vitamin D3 No text entered.
7000IU/d Vitamin D3 No text entered.

Participant Flow:   Overall Study
    4000IU/d of Vitamin D3   7000IU/d Vitamin D3
STARTED   22   22 
COMPLETED   21   21 
NOT COMPLETED   1   1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
4000IU/d of Vitamin D3 No text entered.
7000IU/d Vitamin D3 No text entered.
Total Total of all reporting groups

Baseline Measures
   4000IU/d of Vitamin D3   7000IU/d Vitamin D3   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 22   22   44 
Age 
[Units: Participants]
 		     
<=18 years   9   7   16 
Between 18 and 65 years   13   15   28 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation) 		 18.4  (4.5)   19.1  (5.0)   18.7  (4.7) 
Gender 
[Units: Participants]
 		     
Female   7   7   14 
Male   15   15   30 
Region of Enrollment 
[Units: Participants]
 		     
United States   22   22   44 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Safety   [ Time Frame: 12 weeks ]
  Show Outcome Measure 1

2.  Primary:   Efficacy of the Two Doses (4000 and 7000 IU/d)   [ Time Frame: 12 weeks ]
  Show Outcome Measure 2


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Virginia Stallings
Organization: Children's Hospital of Philadephia
phone: 215-590-1664
e-mail: stallingsv@email.chop.edu


Publications of Results:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier: NCT01092338     History of Changes
Other Study ID Numbers: 09-007332
R01AT005531 ( U.S. NIH Grant/Contract )
Study First Received: March 23, 2010
Results First Received: January 7, 2013
Last Updated: August 1, 2013